- Home
- RMAX vs CHRS Comparison
RMAX vs CHRS Comparison
Compare RMAX & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RMAX | CHRS |
|---|---|---|
| Founded | 1973 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 167.9M | 186.0M |
| IPO Year | 2013 | 2014 |
Fundamental Metrics
Financial Performance| Metric | RMAX | CHRS |
|---|---|---|
| Price | $8.21 | $1.59 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $9.00 | $4.02 |
| AVG Volume (30 Days) | 157.2K | ★ 1.2M |
| Earning Date | 02-19-2026 | 03-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | 0.62 | ★ 1.34 |
| Revenue | ★ $292,931,000.00 | $277,728,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.90 | $67.31 |
| P/E Ratio | $13.16 | ★ $1.23 |
| Revenue Growth | N/A | ★ 152.07 |
| 52 Week Low | $6.90 | $0.71 |
| 52 Week High | $10.67 | $1.89 |
Technical Indicators
Market Signals| Indicator | RMAX | CHRS |
|---|---|---|
| Relative Strength Index (RSI) | 57.27 | 55.52 |
| Support Level | $7.84 | $1.51 |
| Resistance Level | $8.43 | $1.72 |
| Average True Range (ATR) | 0.29 | 0.13 |
| MACD | 0.07 | 0.01 |
| Stochastic Oscillator | 79.17 | 54.33 |
Price Performance
Historical ComparisonAbout RMAX RE/MAX Holdings Inc.
RE/MAX Holdings Inc operates as a franchisor of real estate brokerage services. It recruits and retains agents and sells franchises. The company's operating segments include Real Estate, Mortgage, Marketing Funds, and Others. It generates maximum revenue from the Real Estate segment.
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.